Ram Selvaraju, an analyst from H.C. Wainwright, maintained the Buy rating on Balchem. The associated price target is $189.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Balchem’s strong financial performance and promising growth prospects. The company’s second-quarter financial results for 2025 exceeded expectations, with revenue and net earnings surpassing forecasts. This positive performance is attributed to the strength of the Human Nutrition and Health segment, which significantly outperformed expectations, and the announcement of a new manufacturing facility that could more than double Balchem’s capacity in micro-encapsulation technologies.
Additionally, the imposition of anti-dumping duties on choline chloride imports from China by the European Commission is expected to enhance Balchem’s sales outlook in Europe. The company’s effective tax rate is projected to remain stable, and the modest expansion in valuation multiples within the comparables universe has led to an increased price target. These factors, combined with Balchem’s ability to navigate macroeconomic challenges and potential favorable foreign exchange impacts, support the Buy rating and a raised price target of $189.
In another report released on August 2, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $171.00 price target.